# A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Source: https://onco.cc/trials/nct03899636/  
OnCo record `nct03899636` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Modified FOLFIRINOX Regimen in pancreatic ductal adenocarcinoma, run by Angiodynamics, Inc., active and no longer recruiting.

## Summary

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer is a phase 3 interventional study registered as NCT03899636 by Angiodynamics, Inc., with 528 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2025-04. Interventions recorded: Modified FOLFIRINOX Regimen and NanoKnife System.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03899636
- Phase: 3
- Setting: A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
- Sponsor: Angiodynamics, Inc.
- Enrolled: 528

## Sources

- ClinicalTrials.gov NCT03899636: https://clinicaltrials.gov/study/NCT03899636

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct03899636.json